Advertisement

Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour

Published:December 02, 2022DOI:https://doi.org/10.1016/j.ejca.2022.10.018
      Jones et al. published in a recent issue of the European Journal of Cancer a seminal study describing the long-term efficacy results of new generation tyrosine kinase inhibitor, avapritinib, in a rare subtype of gastrointestinal stromal tumor (GIST), namely PDGFRα D842V-mutant GIST which is primary resistant to imatinib [
      • Jones R.L.
      • Serrano C.
      • von Mehren M.
      • George S.
      • Heinrich M.C.
      • Kang Y.K.
      • et al.
      Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jones R.L.
        • Serrano C.
        • von Mehren M.
        • George S.
        • Heinrich M.C.
        • Kang Y.K.
        • et al.
        Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial.
        Eur J Cancer. 2021 Mar; 145: 132-142
        • Italiano A.
        Next questions for the medical treatment of gastrointestinal stromal tumor.
        Curr Opin Oncol. 2022 Jul 1; 34: 348-353
        • Hostein I.
        • Faur N.
        • Primois C.
        • Boury F.
        • Denard J.
        • Emile J.F.
        • et al.
        BRAF mutation status in gastrointestinal stromal tumors.
        Am J Clin Pathol. 2010 Jan; 133: 141-148
        • Aldea M.
        • Cerbone L.
        • Bayle A.
        • Parisi C.
        • Sarkozy C.
        • Vasseur D.
        • et al.
        Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients.
        Ann Oncol. 2021 Dec; 32: 1642-1645
        • Falchook G.S.
        • Trent J.C.
        • Heinrich M.C.
        • Beadling C.
        • Patterson J.
        • Bastida C.C.
        • et al.
        BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
        Oncotarget. 2013 Feb; 4: 310-315
        • Subbiah V.
        • Baik C.
        • Kirkwood J.M.
        Clinical development of BRAF plus MEK inhibitor combinations.
        Trends Cancer. 2020 Sep; 6: 797-810
        • Johnson D.B.
        • Childress M.A.
        • Chalmers Z.R.
        • Frampton G.M.
        • Ali S.M.
        • Rubinstein S.M.
        • et al.
        BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
        Pigment Cell Melanoma Res. 2018 May; 31: 432-436
        • Wang L.
        • Zhu G.
        • Zhang Q.
        • Duan C.
        • Zhang Y.
        • Zhang Z.
        • et al.
        Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
        Org Biomol Chem. 2017 Apr 18; 15: 3455-3465

      Linked Article